MX370348B - Miembros de la familia il-1 modificados dirigidos. - Google Patents

Miembros de la familia il-1 modificados dirigidos.

Info

Publication number
MX370348B
MX370348B MX2016000723A MX2016000723A MX370348B MX 370348 B MX370348 B MX 370348B MX 2016000723 A MX2016000723 A MX 2016000723A MX 2016000723 A MX2016000723 A MX 2016000723A MX 370348 B MX370348 B MX 370348B
Authority
MX
Mexico
Prior art keywords
family member
cytokine
modified
mutant
family members
Prior art date
Application number
MX2016000723A
Other languages
English (en)
Other versions
MX2016000723A (es
Inventor
Tavernier Jan
Uzé Gilles
Gerlo Sarah
Peelman Frank
Original Assignee
Vib Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw filed Critical Vib Vzw
Publication of MX2016000723A publication Critical patent/MX2016000723A/es
Publication of MX370348B publication Critical patent/MX370348B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una composición que comprende una construcción de direccionamiento, caracterizada porque comprende: (1) una IL-1ß mutada caracterizada por una afinidad reducida por su receptor en comparación con la IL-1ß silvestre, en donde la IL-1ß mutada comprende una o más mutaciones seleccionadas de R120X, Q131G, L145G, H146X, Q148X, F162A, y R208E, en donde X es un cambio no conservador, y (2) una porción direccionamiento que comprende un dominio variable de anticuerpos de cadena pesada de camélido (VHH) o un dominio variable de nuevos receptores de antígeno (VNAR).
MX2016000723A 2013-07-19 2014-07-04 Miembros de la familia il-1 modificados dirigidos. MX370348B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306047 2013-07-19
PCT/EP2014/064283 WO2015007542A1 (en) 2013-07-19 2014-07-04 Targeted modified il-1 family members

Publications (2)

Publication Number Publication Date
MX2016000723A MX2016000723A (es) 2016-12-20
MX370348B true MX370348B (es) 2019-12-10

Family

ID=48874235

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000723A MX370348B (es) 2013-07-19 2014-07-04 Miembros de la familia il-1 modificados dirigidos.

Country Status (14)

Country Link
US (5) US9932409B2 (es)
EP (1) EP3022226B1 (es)
JP (1) JP6475713B2 (es)
KR (1) KR102275090B1 (es)
CN (1) CN105612180B (es)
AU (1) AU2014292377B2 (es)
BR (1) BR112016001128A2 (es)
CA (1) CA2918518C (es)
DK (1) DK3022226T3 (es)
ES (1) ES2714504T3 (es)
IL (1) IL243466B (es)
MX (1) MX370348B (es)
SG (1) SG11201600167SA (es)
WO (1) WO2015007542A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180083868A (ko) * 2015-10-30 2018-07-23 알레타 바이오쎄라퓨틱스, 인크. 종양 형질도입용 조성물 및 방법
EP3368559A4 (en) 2015-10-30 2020-01-15 Aleta Biotherapeutics Inc. COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
WO2017134305A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Bispecific signaling agents and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CA3023881A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
JP7105200B2 (ja) 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ 標的突然変異体インターフェロン－ベータおよびその使用
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
JP2020505955A (ja) 2017-02-06 2020-02-27 オリオンズ バイオサイエンス インコーポレイテッド 標的化改変型インターフェロン及びその使用
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
JP2020511528A (ja) * 2017-03-03 2020-04-16 オブシディアン セラピューティクス， インコーポレイテッド 免疫療法のための組成物及び方法
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN110997725A (zh) 2017-06-12 2020-04-10 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Ｐｄ－１およびｐｄ－ｌ１結合物質
JP7347899B2 (ja) 2017-08-09 2023-09-20 オリオンズ バイオサイエンス インコーポレイテッド Ｃｄ８結合物質
EP3733716A4 (en) * 2017-12-26 2021-11-24 Nanjing GenScript Biotech Co., Ltd. DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE
MX2020008208A (es) 2018-02-05 2020-11-09 Orionis Biosciences Inc Agentes de unión a fibroblastos y uso de estos.
US11440943B2 (en) 2019-03-28 2022-09-13 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins
WO2022011005A1 (en) * 2020-07-07 2022-01-13 Orionis Biosciences, Inc. Immunostimulatory adjuvants

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE103932T1 (de) 1989-08-22 1994-04-15 Immunex Corp Fusionsprotein bestehend aus gm-csf und il-3.
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) * 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
WO2001029870A1 (en) * 1999-10-21 2001-04-26 Sarnoff Corporation Bi-potential electrode space-saving cathode ray tube
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
WO2008014612A1 (en) 2006-08-02 2008-02-07 Mcgill University Fusion proteins and methods for modulation of immune response
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
EP2173377B1 (en) * 2007-06-26 2017-11-29 University of Miami Antibody-endostatin fusion protein and its variants
CN108129573B (zh) 2007-09-21 2021-10-08 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
WO2010036918A2 (en) * 2008-09-26 2010-04-01 University Of Massachusetts Intracellular dna receptor
JP2012510806A (ja) 2008-12-08 2012-05-17 コンプリクス エン ヴェー 単鎖逆平行コイルドコイルタンパク質
EP2467165B1 (en) * 2009-08-17 2015-01-07 Roche Glycart AG Targeted immunoconjugates
US20130115189A1 (en) 2009-09-10 2013-05-09 Cytos Biotechnology Ag Use of Interleukin-1 Beta Mutein Conjugates in the Treatment of Diabetes
US9534056B2 (en) 2011-06-06 2017-01-03 Immungene Inc Engineered TAA antibody-TNFSF member ligand fusion molecules
BR112014009925B1 (pt) 2011-10-28 2022-09-20 Teva Pharmaceuticals Australia Pty Ltd Construtores de polipeptídeos e seus usos
CA2861927C (en) 2012-01-20 2021-01-26 Vib Vzw Targeted mutant alpha-helical bundle cytokines
WO2013134138A1 (en) 2012-03-03 2013-09-12 Immungene, Inc. Engineered antibody-interferon mutant fusion molecules

Also Published As

Publication number Publication date
CN105612180B (zh) 2019-11-12
KR20160108293A (ko) 2016-09-19
US20200255545A1 (en) 2020-08-13
US9932409B2 (en) 2018-04-03
CN105612180A (zh) 2016-05-25
CA2918518A1 (en) 2015-01-22
SG11201600167SA (en) 2016-02-26
JP6475713B2 (ja) 2019-02-27
KR102275090B1 (ko) 2021-07-09
DK3022226T3 (en) 2019-03-25
BR112016001128A2 (pt) 2018-01-23
US20230235086A1 (en) 2023-07-27
IL243466B (en) 2019-11-28
MX2016000723A (es) 2016-12-20
AU2014292377B2 (en) 2019-08-01
US20160152730A1 (en) 2016-06-02
IL243466A0 (en) 2016-03-31
CA2918518C (en) 2022-08-16
US20180186894A1 (en) 2018-07-05
WO2015007542A1 (en) 2015-01-22
EP3022226B1 (en) 2018-12-05
EP3022226A1 (en) 2016-05-25
AU2014292377A1 (en) 2016-02-04
US20190202934A1 (en) 2019-07-04
JP2016527221A (ja) 2016-09-08
ES2714504T3 (es) 2019-05-28

Similar Documents

Publication Publication Date Title
MX2016000723A (es) Miembros de la familia il-1 modificados dirigidos.
MX370565B (es) Miembros de la familia tnf modificados dirigidos.
AU2013211059A8 (en) Targeted mutant alpha-helical bundle cytokines
JO3532B1 (ar) الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EP3604535A3 (en) Methods and compositions for weed control
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
PH12016500781A1 (en) Novel anti-claudin antibodies and methods of use
EP4324480A3 (en) Anti-transferrin receptor antibodies and methods of use
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
MX2017016811A (es) Metodos para mejorar el rendimiento del animal.
ECSP14013148A (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
BR112015023557A2 (pt) proteínas de ligações dual específicas direcionadas contra tnfa
WO2011143318A3 (en) Anti-fgfr2 antibodies
WO2012175222A8 (en) AN IL-15 AND IL-15Rα SUSHI DOMAIN BASED IMMUNOCYTOKINES
MY167920A (en) HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
PH12016500425A1 (en) Il-18 binding protein (il-18bp) in inflammatory diseases
MX2016007369A (es) Nuevos anticuerpos anti-dpep3 y metodos de uso.
MX2016000611A (es) Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
MX2015006859A (es) Anticuerpos anti-vegf y sus usos.
EP4349864A3 (en) Oncostatin m receptor antigen binding proteins
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
EA201690992A1 (ru) Антитела, специфичные к fcrn

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: NOVOZYMES A/S

FG Grant or registration